ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity

View Author Information
Schering-Plough Research Institute, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
* To whom correspondence should be addressed. Phone: 908-740-3474 . Fax: 908-740-7164. E-mail: [email protected]
Cite this: J. Med. Chem. 2008, 51, 11, 3061–3064
Publication Date (Web):May 1, 2008
Copyright © 2008 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described. Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    Jump To

    Experimental procedures for platelet aggregation studies, PAR-1 binding assay, and synthesis and characterization of intermediates and selected final products. This material is available free of charge via Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 220 publications.

    1. Panpan Chen, Cai Chen, Yizheng Zheng, Fangjun Chen, Zhaojun Liu, Shenhong Ren, Hangyu Song, Tongdan Liu, Zhipeng Lu, Hongbin Sun, Yi Kong, Haoliang Yuan. Discovery of 2,3-Dihydro[1,4]dioxino[2,3-g]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency. Journal of Medicinal Chemistry 2024, 67 (7) , 5502-5537.
    2. E. Scott Priestley, Jacques Banville, Daniel Deon, Laurence Dubé, Marc Gagnon, Julia Guy, Philippe Lapointe, Jean-François Lavallée, Alain Martel, Serge Plamondon, Roger Rémillard, Edward Ruediger, François Tremblay, Shana L. Posy, Victor R. Guarino, Jeremy M. Richter, Jianqing Li, Anuradha Gupta, Muthalagu Vetrichelvan, T. J. Balapragalathan, Arvind Mathur, Ji Hua, Mario Callejo, Jocelyne Guay, Chi Shing Sum, Mary Ellen Cvijic, Carol Watson, Pancras Wong, Jing Yang, Michel Bouvier, David A. Gordon, Ruth R. Wexler, Anne Marinier. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. Journal of Medicinal Chemistry 2022, 65 (13) , 8843-8854.
    3. Mihirbaran Mandal, Maria Madeira, Rupesh P. Amin, Alexei V. Buevich, Alan Cheng, Marc Labroli, Xiaoxiang Liu, John Acton, Barbara Pio, Andrea Basso, Harry Chobanian, Grace Dong, Jamie Dropinski, Yan Guo, Zhuyan Guo, Stan Kurowski, Walter Korfmacher, Sandra Lee, Dongfang Meng, Debra Ondeyka, Zhiqiang Yang, Rumin Zhang, Huijun Wei, Zhicai Wu, Fengqi Zhang, Gordon Wollenberg, Tesfaye Biftu, William J. Greenlee, Madhu Chintala, Milana Maletic, Zhaoning Zhu. Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early Discovery. Journal of Medicinal Chemistry 2022, 65 (7) , 5575-5592.
    4. Audrey E. Yñigez-Gutierrez, Brian O. Bachmann. Fixing the Unfixable: The Art of Optimizing Natural Products for Human Medicine. Journal of Medicinal Chemistry 2019, 62 (18) , 8412-8428.
    5. Benjamin J. Huffman, Ryan A. Shenvi. Natural Products in the “Marketplace”: Interfacing Synthesis and Biology. Journal of the American Chemical Society 2019, 141 (8) , 3332-3346.
    6. Mark W. Majewski, Disha M. Gandhi, Ricardo Rosas, Jr., Revathi Kodali, Leggy A. Arnold, Chris Dockendorff. Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization. ACS Medicinal Chemistry Letters 2019, 10 (1) , 121-126.
    7. Michael D. Delost, David T. Smith, Benton J. Anderson, Jon T. Njardarson. From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles. Journal of Medicinal Chemistry 2018, 61 (24) , 10996-11020.
    8. Michael P. Bokoch, Hyunil Jo, James R. Valcourt, Yoga Srinivasan, Albert C. Pan, Sara Capponi, Michael Grabe, Ron O. Dror, David E. Shaw, William F. DeGrado, Shaun R. Coughlin. Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule. Biochemistry 2018, 57 (39) , 5748-5758.
    9. Ya Chen, Christina de Bruyn Kops, and Johannes Kirchmair . Data Resources for the Computer-Guided Discovery of Bioactive Natural Products. Journal of Chemical Information and Modeling 2017, 57 (9) , 2099-2111.
    10. Dilip K. Tosh, Antonella Ciancetta, Eugene Warnick, Steven Crane, Zhan-Guo Gao, and Kenneth A. Jacobson . Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists. Journal of Medicinal Chemistry 2016, 59 (24) , 11006-11026.
    11. Yu Zhou, Jiang Wang, Zhanni Gu, Shuni Wang, Wei Zhu, José Luis Aceña, Vadim A. Soloshonok, Kunisuke Izawa, and Hong Liu . Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chemical Reviews 2016, 116 (2) , 422-518.
    12. Reed T. Larson, Ryan P. Pemberton, Jenna M. Franke, Dean J. Tantillo, and Regan J. Thomson . Total Synthesis of the Galbulimima Alkaloids Himandravine and GB17 Using Biomimetic Diels–Alder Reactions of Double Diene Precursors. Journal of the American Chemical Society 2015, 137 (34) , 11197-11204.
    13. Mariappan V. Chelliah, Keith Eagen, Zhuyan Guo, Samuel Chackalamannil, Yan Xia, Hsingan Tsai, William J. Greenlee, Ho-Sam Ahn, Stan Kurowski, George Boykow, Yunsheng Hsieh, and Madhu Chintala . Himbacine-Derived Thrombin Receptor Antagonists: C7-Spirocyclic Analogues of Vorapaxar. ACS Medicinal Chemistry Letters 2014, 5 (5) , 561-565.
    14. Mariappan V. Chelliah, Samuel Chackalamannil, Yan Xia, William J. Greenlee, Ho-Sam Ahn, Stan Kurowski, George Boykow, Yunsheng Hsieh, and Madhu Chintala . Himbacine-Derived Thrombin Receptor Antagonists: C7-Aminomethyl and C9a-Hydroxy Analogues of Vorapaxar. ACS Medicinal Chemistry Letters 2014, 5 (2) , 183-187.
    15. Sunkyung Lee, Jong-Hwan Song, Chul Min Park, Jin-Seok Kim, Ji-Hye Jeong, Woo-Young Cho, and Dong-Chul Lim . Discovery of Octahydroindenes as PAR1 Antagonists. ACS Medicinal Chemistry Letters 2013, 4 (11) , 1054-1058.
    16. Kelvin Kau Kiat Goh, Sunggak Kim, and Samir Z. Zard . Free-Radical Variant for the Synthesis of Functionalized 1,5-Diketones. Organic Letters 2013, 15 (18) , 4818-4821.
    17. Giuseppe Caliendo, Vincenzo Santagada, Elisa Perissutti, Beatrice Severino, Ferdinando Fiorino, Francesco Frecentese, and Luiz Juliano . Kallikrein Protease Activated Receptor (PAR) Axis: An Attractive Target for Drug Development. Journal of Medicinal Chemistry 2012, 55 (15) , 6669-6686.
    18. David A. Evans, Drew J. Adams, and Eugene E. Kwan . Progress toward the Syntheses of (+)-GB 13, (+)-Himgaline, and Himandridine. New Insights into Intramolecular Imine/Enamine Aldol Cyclizations. Journal of the American Chemical Society 2012, 134 (19) , 8162-8170.
    19. Chris Dockendorff, Omozuanvbo Aisiku, Lynn VerPlank, James R. Dilks, Daniel A. Smith, Susanna F. Gunnink, Louisa Dowal, Joseph Negri, Michelle Palmer, Lawrence MacPherson, Stuart L. Schreiber, and Robert Flaumenhaft . Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Medicinal Chemistry Letters 2012, 3 (3) , 232-237.
    20. Yifeng Xiong, Bradley R. Teegarden, Jin-Sun Karoline Choi, Sonja Strah-Pleynet, Marc Decaire, Honnappa Jayakumar, Peter I. Dosa, Martin D. Casper, Lan Pham, Konrad Feichtinger, Brett Ullman, John Adams, Diane Yuskin, John Frazer, Michael Morgan, Abu Sadeque, Weichao Chen, Robert R. Webb, Daniel T. Connolly, Graeme Semple and Hussien Al-Shamma. Discovery and Structure−Activity Relationship of 3-Methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): A Highly Selective 5-Hydroxytryptamine2A Receptor Inverse Agonist for the Treatment of Arterial Thrombosis. Journal of Medicinal Chemistry 2010, 53 (11) , 4412-4421.
    21. Mohammad Movassaghi, Meiliana Tjandra and Jun Qi. Total Synthesis of (−)-Himandrine. Journal of the American Chemical Society 2009, 131 (28) , 9648-9650.
    22. Modesto de Candia, Francesco Liantonio, Andrea Carotti, Raimondo De Cristofaro and Cosimo Altomare. Fluorinated Benzyloxyphenyl Piperidine-4-carboxamides with Dual Function against Thrombosis: Inhibitors of Factor Xa and Platelet Aggregation. Journal of Medicinal Chemistry 2009, 52 (4) , 1018-1028.
    23. Alexandre Slater, Sophia Khattak, Mark R Thomas. GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease. European Heart Journal - Cardiovascular Pharmacotherapy 2024, 11
    24. Ruslan Bohovyk, Sherif Khedr, Vladislav Levchenko, Mariia Stefanenko, Marharyta Semenikhina, Olha Kravtsova, Elena Isaeva, Aron M. Geurts, Christine A. Klemens, Oleg Palygin, Alexander Staruschenko. Protease-Activated Receptor 1–Mediated Damage of Podocytes in Diabetic Nephropathy. Diabetes 2023, 72 (12) , 1795-1808.
    25. Liwen Deng, Flavia Costa, Kimbria J. Blake, Samantha Choi, Arundhasa Chandrabalan, Muhammad Saad Yousuf, Stephanie Shiers, Daniel Dubreuil, Daniela Vega-Mendoza, Corinne Rolland, Celine Deraison, Tiphaine Voisin, Michelle D. Bagood, Lucia Wesemann, Abigail M Frey, Joseph S. Palumbo, Brian J. Wainger, Richard L. Gallo, Juan-Manuel Leyva-Castillo, Nathalie Vergnolle, Theodore J. Price, Rithwik Ramachandran, Alexander R. Horswill, Isaac M. Chiu. S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis. Cell 2023, 186 (24) , 5375-5393.e25.
    26. Corey M. Webster, Jan M. van Deursen. Senolysis through thrombomodulation. Cell Research 2023, 33 (8) , 575-576.
    27. Dennis W. T. Nilsen, Michelle Røysland, Thor Ueland, Pål Aukrust, Annika E. Michelsen, Harry Staines, Ståle Barvik, Frederic Kontny, Jan Erik Nordrehaug, Vernon V. S. Bonarjee. The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease. Thrombosis and Haemostasis 2023, 123 (05) , 510-521.
    28. Xiao You, Wenning Zhu, Jiacheng Du, Yuehua Liu, Fumin Chen, Yongshuai Chai, Qiang Zhang, Jingxiang Pang, Aiqin Liu, Zhushuang Bai. Organocatalytic asymmetric Michael addition reaction of aldehydes with 2-furanones: experimental, applications and DFT studies. Organic Chemistry Frontiers 2023, 10 (6) , 1527-1536.
    29. Chloe J. Peach, Laura E. Edgington-Mitchell, Nigel W. Bunnett, Brian L. Schmidt. Protease-activated receptors in health and disease. Physiological Reviews 2023, 103 (1) , 717-785.
    30. Stone Woo, Eleanor M. Landwehr, Ryan A. Shenvi. Synthesis of psychotropic alkaloids from Galbulimima. Tetrahedron 2022, 126 , 133064.
    31. Samuel Chackalamannil. A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivity™). Medicinal Chemistry Research 2022, 31 (10) , 1623-1636.
    32. Ying-Ting Lin, Yu Li, Hui-Ching Hsu, Ju-Ying Tsai, Jia-Hau Lee, Chi-Jung Tai, Ming-Jung Wu, Chin-Chung Wu. Discovery of 7, 4′-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice. Biochemical Pharmacology 2022, 202 , 115152.
    33. Jackson T. Mollel, Joanna S. Said, Rose J. Masalu, Charles Hannoun, Mourice V.N. Mbunde, Ramadhani S.O. Nondo, Tomas Bergström, Edward Trybala. Anti-respiratory syncytial virus and anti-herpes simplex virus activity of six Tanzanian medicinal plants with extended studies of Erythrina abyssinica stem bark. Journal of Ethnopharmacology 2022, 292 , 115204.
    34. Safir Ullah Khan, Munir Ullah Khan, Fadia Kalsoom, Muhammad Imran Khan, Shuang Gao, Ahsanullah Unar, Muhammad Zubair, Muhammad Bilal. Mechanisms of gene regulation by histone degradation in adaptation of yeast: an overview of recent advances. Archives of Microbiology 2022, 204 (5)
    35. Shweta Sinha, Kuldeep Singh, Akash Ved, Syed Misbahul Hasan, Samar Mujeeb. Therapeutic Journey and Recent Advances in the Synthesis of Coumarin Derivatives. Mini-Reviews in Medicinal Chemistry 2022, 22 (9) , 1314-1330.
    36. Majid. M. Heravi, Azadeh Nazari. Samarium( ii ) iodide-mediated reactions applied to natural product total synthesis. RSC Advances 2022, 12 (16) , 9944-9994.
    37. Eleanor M. Landwehr, Meghan A. Baker, Takuya Oguma, Hannah E. Burdge, Takahiro Kawajiri, Ryan A. Shenvi. Concise syntheses of GB22, GB13, and himgaline by cross-coupling and complete reduction. Science 2022, 375 (6586) , 1270-1274.
    38. Harrison T. Shanley, Aya C. Taki, Joseph J. Byrne, Abdul Jabbar, Tim N. C. Wells, Kirandeep Samby, Peter R. Boag, Nghi Nguyen, Brad E. Sleebs, Robin B. Gasser. A High-Throughput Phenotypic Screen of the ‘Pandemic Response Box’ Identifies a Quinoline Derivative with Significant Anthelmintic Activity. Pharmaceuticals 2022, 15 (2) , 257.
    39. Hossein Hosseinzadeh, Marjan Nassiri-Asl. Anticoagulants and Antiplatelet Drugs. 2022, 605-633.
    40. C.H. McAteer, R. Murugan, J.H. Yamamoto. Pyridines and Their Benzo Derivatives: Applications. 2022, 217-242.
    41. Jean-Paul Motta, Celine Deraison, Sylvie Le Grand, Bruno Le Grand, Nathalie Vergnolle. PAR-1 Antagonism to Promote Gut Mucosa Healing in Crohn’s Disease Patients: A New Avenue for CVT120165. Inflammatory Bowel Diseases 2021, 27 (Supplement_2) , S33-S37.
    42. Barry W. Festoff, Chris Dockendorff. The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies. Biomolecules 2021, 11 (11) , 1558.
    43. Shaoyi Sun, Steven S. Wesolowski. Biologically active metabolites in drug discovery. Bioorganic & Medicinal Chemistry Letters 2021, 48 , 128255.
    44. M.S.J. Arnold, J.R. Macdonald, R.J. Quinn, T.S. Skinner-Adams, K.T. Andrews, G.M. Fisher. Antiplasmodial activity of the natural product compounds alstonine and himbeline. International Journal for Parasitology: Drugs and Drug Resistance 2021, 16 , 17-22.
    45. Samuel Chackalamannil. Antiplatelet Agents. 2021, 1-70.
    46. Arundhasa Chandrabalan, Rithwik Ramachandran. Molecular mechanisms regulating Proteinase‐Activated Receptors (PARs). The FEBS Journal 2021, 288 (8) , 2697-2726.
    47. Chang Hoon Lee, Dominick J. Angiolillo. Platelet physiology and pharmacology—relevant considerations for patient care. 2021, 15-45.
    48. Safir Ullah Khan, Munir Ullah Khan. A Scientific Breakthrough in the Regulatory Mechanism of Histone Degradation. SSRN Electronic Journal 2021, 389
    49. Xu Han, Marvin T. Nieman. The domino effect triggered by the tethered ligand of the protease activated receptors. Thrombosis Research 2020, 196 , 87-98.
    50. Haibo Mei, Jianlin Han, Sarah White, Daniel J. Graham, Kunisuke Izawa, Tatsunori Sato, Santos Fustero, Nicholas A. Meanwell, Vadim A. Soloshonok. Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals. Chemistry – A European Journal 2020, 26 (50) , 11349-11390.
    51. Udaya S Tantry, Kevin P Bliden, Rahul Chaudhary, Marko Novakovic, Amit Rout, Paul A Gurbel. Vorapaxar in the Treatment of Cardiovascular Diseases. Future Cardiology 2020, 16 (5) , 373-384.
    52. Christoph B Olivier, Vandana Sundaram, Glenn M Chertow, Sumana Shashidhar, Lori K McDonnell, Victoria Y Ding, Manisha Desai, Kenneth W Mahaffey, Matthew Mell. A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. The Journal of Vascular Access 2020, 21 (4) , 467-474.
    53. Bernhard Kutscher. Antithrombotics ( B01 ) and Antihemorrhagics ( B02 ). 2020, 1-34.
    54. Xian Li, Martha M.S. Sim, Jeremy P. Wood. Recent Insights Into the Regulation of Coagulation and Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2020, 40 (5)
    55. Daisuke Noguchi, Naohisa Kuriyama, Takahiro Ito, Takehiro Fujii, Hiroyuki Kato, Shugo Mizuno, Hiroyuki Sakurai, Shuji Isaji. Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury. Journal of Surgical Research 2020, 246 , 568-583.
    56. Piotr P. Graczyk, Sven Nerdinger. Mini-Review: The Chemistry of Vorapaxar – Is There Any Room for Improvement Left?. HETEROCYCLES 2020, 101 (2) , 373.
    57. Nicholas Tomko, Mark Kluever, Chunying Wu, Junqing Zhu, Yanming Wang, Robert G. Salomon. 4-Hydroxy-7-oxo-5-heptenoic acid lactone is a potent inducer of brain cancer cell invasiveness that may contribute to the failure of anti-angiogenic therapies. Free Radical Biology and Medicine 2020, 146 , 234-256.
    58. Orla Willis Fox, Roger J.S. Preston. Molecular basis of protease‐activated receptor 1 signaling diversity. Journal of Thrombosis and Haemostasis 2020, 18 (1) , 6-16.
    59. Dorothea M. Heuberger, Reto A. Schuepbach. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thrombosis Journal 2019, 17 (1)
    60. Frederic Bassilana, Mark Nash, Marie-Gabrielle Ludwig. Adhesion G protein-coupled receptors: opportunities for drug discovery. Nature Reviews Drug Discovery 2019, 18 (11) , 869-884.
    61. Robert B. Laprairie, Kiran Vemuri, Edward L. Stahl, Anisha Korde, Jo-Hao Ho, Travis W. Grim, Tian Hua, Yiran Wu, Raymond C. Stevens, Zhi-Jie Liu, Alexandros Makriyannis, Laura M. Bohn. Probing the CB 1 Cannabinoid Receptor Binding Pocket with AM6538, a High-Affinity Irreversible Antagonist. Molecular Pharmacology 2019, 96 (5) , 619-628.
    62. Chul Min Park, Sunkyung Lee, Jong‐Hwan Song, Joo‐Youn Lee. Discovery of ( E )‐5,5‐Difluoro‐1‐[2‐[5‐(3‐fluorophenyl)pyridin‐2‐yl]vinyl]octahydrospiro(indene‐2,5′‐oxazolidin)‐2′‐one as a PAR1 Antagonist. Bulletin of the Korean Chemical Society 2019, 40 (7) , 658-667.
    63. Xu Han, Emma G. Bouck, Elizabeth R. Zunica, Amal Arachiche, Marvin T. Nieman. Protease-Activated Receptors. 2019, 243-257.
    64. Kumaran Kolandaivelu, Deepak L. Bhatt. Novel Antiplatelet Therapies. 2019, 991-1015.
    65. Emiko Shinozawa, Masaharu Nakayama, Yoshimi Imura. TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1. Frontiers in Pharmacology 2018, 9
    66. Asmita Pant, Anna K. Kopec, James P. Luyendyk. Role of the blood coagulation cascade in hepatic fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2018, 315 (2) , G171-G176.
    67. Patrizia M. Spoerri, Hideaki E. Kato, Moritz Pfreundschuh, Stefania A. Mari, Tetiana Serdiuk, Johannes Thoma, K. Tanuj Sapra, Cheng Zhang, Brian K. Kobilka, Daniel J. Müller. Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist. Structure 2018, 26 (6) , 829-838.e4.
    68. Dean G. Brown, Giles A. Brown, Paolo Centrella, Kaan Certel, Robert M. Cooke, John W. Cuozzo, Niek Dekker, Christoph E. Dumelin, Andrew Ferguson, Cédric Fiez-Vandal, Stefan Geschwindner, Marie-Aude Guié, Sevan Habeshian, Anthony D. Keefe, Oliver Schlenker, Eric A. Sigel, Arjan Snijder, Holly T. Soutter, Linda Sundström, Dawn M. Troast, Giselle Wiggin, Jing Zhang, Ying Zhang, Matthew A. Clark. Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target. SLAS Discovery 2018, 23 (5) , 429-436.
    69. Disha M. Gandhi, Mark W. Majewski, Ricardo Rosas, Kaitlin Kentala, Trevor J. Foster, Eric Greve, Chris Dockendorff. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells. Bioorganic & Medicinal Chemistry 2018, 26 (9) , 2514-2529.
    70. Koji Sugiyama, Shinji Kawanishi, Yasuhiro Oki, Marin Kamiya, Ryosuke Hanada, Masahiro Egi, Shuji Akai. Lipase-catalyzed asymmetric synthesis of naphtho[2,3-c]furan-1(3H)-one derivatives by a one-pot dynamic kinetic resolution/intramolecular Diels–Alder reaction: Total synthesis of (−)-himbacine. Bioorganic & Medicinal Chemistry 2018, 26 (7) , 1378-1386.
    71. Nigel Mackman, Henri M.H. Spronk, George A. Stouffer, Hugo ten Cate. Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. Arteriosclerosis, Thrombosis, and Vascular Biology 2018, 38 (4) , 726-732.
    72. Theodora A. M. Claushuis, Alex F. de Vos, Bernard Nieswandt, Louis Boon, Joris J. T. H. Roelofs, Onno J. de Boer, Cornelis van ’t Veer, Tom van der Poll. Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteria. Blood 2018, 131 (8) , 864-876.
    73. Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. Journal of Cardiovascular Pharmacology and Therapeutics 2018, 23 (1) , 23-37.
    74. Khalid Al-Khafaji, Monica Mutyala, Nawfal Al-Khafaji, Yenal Harper, Imtiaz Ismail, Hosam Hakim, Rohit R. Arora. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis. American Journal of Therapeutics 2017, 24 (6) , e730-e736.
    75. Weilong Zhong, Pi Liu, Qiang Zhang, Dongmei Li, Jianping Lin. Structure-based QSAR, molecule design and bioassays of protease-activated receptor 1 inhibitors. Journal of Biomolecular Structure and Dynamics 2017, 35 (13) , 2853-2867.
    76. Carolyn Readmond, Chun Wu. Investigating detailed interactions between novel PAR1 antagonist F16357 and the receptor using docking and molecular dynamic simulations. Journal of Molecular Graphics and Modelling 2017, 77 , 205-217.
    77. Bart L. van den Eshof, Arie J. Hoogendijk, Pelle J. Simpson, Floris P.J. van Alphen, Sara Zanivan, Koen Mertens, Alexander B. Meijer, Maartje van den Biggelaar. Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics. Arteriosclerosis, Thrombosis, and Vascular Biology 2017, 37 (10) , 1891-1902.
    78. Flávia S Frattani, Lidia M Lima, Eliezer J Barreiro, Russolina B Zingali. The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats. Journal of Pharmacy and Pharmacology 2017, 69 (10) , 1374-1380.
    79. Robert Flaumenhaft, Karen De Ceunynck. Targeting PAR1: Now What?. Trends in Pharmacological Sciences 2017, 38 (8) , 701-716.
    80. P.J. Vinholt, H. Frederiksen, A.‐M. Hvas, U. Sprogøe, C. Nielsen. Measurement of platelet aggregation, independently of patient platelet count: a flow‐cytometric approach. Journal of Thrombosis and Haemostasis 2017, 15 (6) , 1191-1202.
    81. Oscar Benimana, Lulu Zhao, Yi Kong, Zhiyu Li, Zhouling Xie. The Progress in the Research of Antiplatelet Agents (1995–2017). Future Medicinal Chemistry 2017, 9 (10) , 1087-1110.
    82. Robert K. Y. Cheng, Cédric Fiez-Vandal, Oliver Schlenker, Karl Edman, Birte Aggeler, Dean G. Brown, Giles A. Brown, Robert M. Cooke, Christoph E. Dumelin, Andrew S. Doré, Stefan Geschwindner, Christoph Grebner, Nils-Olov Hermansson, Ali Jazayeri, Patrik Johansson, Louis Leong, Rudi Prihandoko, Mathieu Rappas, Holly Soutter, Arjan Snijder, Linda Sundström, Benjamin Tehan, Peter Thornton, Dawn Troast, Giselle Wiggin, Andrei Zhukov, Fiona H. Marshall, Niek Dekker. Structural insight into allosteric modulation of protease-activated receptor 2. Nature 2017, 545 (7652) , 112-115.
    83. Rithwik Ramachandran, Koichiro Mihara, Pierre Thibeault, Christina M. Vanderboor, Björn Petri, Mahmoud Saifeddine, Michel Bouvier, Morley D. Hollenberg. Targeting a Proteinase-Activated Receptor 4 (PAR4) Carboxyl Terminal Motif to Regulate Platelet Function. Molecular Pharmacology 2017, 91 (4) , 287-295.
    84. T.A.M. Claushuis, S.F. de Stoppelaar, I. Stroo, J.J.T.H. Roelofs, R. Ottenhoff, T. van der Poll, C. van‘t Veer. Thrombin contributes to protective immunity in pneumonia‐derived sepsis via fibrin polymerization and platelet–neutrophil interactions. Journal of Thrombosis and Haemostasis 2017, 15 (4) , 744-757.
    85. Weilong Zhong, Shuang Chen, Qiang Zhang, Ting Xiao, Yuan Qin, Ju Gu, Bo Sun, Yanrong Liu, Xiangyan Jing, Xuejiao Hu, Peng Zhang, Honggang Zhou, Tao Sun, Cheng Yang. Doxycycline directly targets PAR1 to suppress tumor progression. Oncotarget 2017, 8 (10) , 16829-16842.
    86. Jose-Angel Perez-Rivera, Jairo Monedero-Campo, Clara Cieza-Borrella, Pablo Ruiz-Perez. Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome. Expert Opinion on Drug Metabolism & Toxicology 2017, 13 (3) , 339-350.
    87. Rebecca J. Gryka, Leo F. Buckley, Sarah M. Anderson. Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. Drugs in R&D 2017, 17 (1) , 65-72.
    88. Zongru Guo. The modification of natural products for medical use. Acta Pharmaceutica Sinica B 2017, 7 (2) , 119-136.
    89. Iraklis C. Moschonas, Alexandros D. Tselepis. Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus. Journal of Cardiovascular Pharmacology and Therapeutics 2017, 22 (2) , 133-141.
    90. Gulraiz Ahmad, Nasir Rasool, Hafiz Ikram, Samreen Gul Khan, Tariq Mahmood, Khurshid Ayub, Muhammad Zubair, Eman Al-Zahrani, Usman Ali Rana, Muhammad Akhtar, Noorjahan Alitheen. Efficient Synthesis of Novel Pyridine-Based Derivatives via Suzuki Cross-Coupling Reaction of Commercially Available 5-Bromo-2-methylpyridin-3-amine: Quantum Mechanical Investigations and Biological Activities. Molecules 2017, 22 (2) , 190.
    91. Justin R. Hamilton, JoAnn Trejo. Challenges and Opportunities in Protease-Activated Receptor Drug Development. Annual Review of Pharmacology and Toxicology 2017, 57 (1) , 349-373.
    92. Pancras C. Wong, Dietmar Seiffert, J. Eileen Bird, Carol A. Watson, Jeffrey S. Bostwick, Mary Giancarli, Nick Allegretto, Ji Hua, David Harden, Jocelyne Guay, Mario Callejo, Michael M. Miller, R. Michael Lawrence, Jacques Banville, Julia Guy, Brad D. Maxwell, E. Scott Priestley, Anne Marinier, Ruth R. Wexler, Michel Bouvier, David A. Gordon, William A. Schumacher, Jing Yang. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Science Translational Medicine 2017, 9 (371)
    93. E.A. Meyer, E. Caroff, M.A. Riederer. Advances in Antiplatelet Agents. 2017, 556-599.
    94. Jin Xiang, Eugene Chun, Chang Liu, Liang Jing, Zina Al-Sahouri, Lan Zhu, Wei Liu. Successful Strategies to Determine High-Resolution Structures of GPCRs. Trends in Pharmacological Sciences 2016, 37 (12) , 1055-1069.
    95. Leo Ungar, Fatima Rodriguez, Kenneth W. Mahaffey. Vorapaxar. Coronary Artery Disease 2016, 27 (7) , 604-615.
    96. Rithwik Ramachandran, Christophe Altier, Katerina Oikonomopoulou, Morley D. Hollenberg, . Proteinases, Their Extracellular Targets, and Inflammatory Signaling. Pharmacological Reviews 2016, 68 (4) , 1110-1142.
    97. Chul Min Park, Songhyun Baek, Seongwoo Kim, Jong-Hwan Song, Sunkyung Lee, Min Kim. Trans-fused 5-[(tert-Butoxtycarbonyl)amino]octahydroindenes as a protease activated receptor-1 (PAR1) antagonist. Archives of Pharmacal Research 2016, 39 (9) , 1275-1295.
    98. Ying Wang, Jinfeng Liu, Tong Zhu, Lujia Zhang, Xiao He, John Z.H. Zhang. Predicted PAR1 inhibitors from multiple computational methods. Chemical Physics Letters 2016, 659 , 295-303.
    99. Sonja Stahn, Lisa Thelen, Ina‐Maria Albrecht, Jens Bitzer, Thomas Henkel, Nicole Elisabeth Teusch. Teleocidin A2 inhibits human proteinase‐activated receptor 2 signaling in tumor cells. Pharmacology Research & Perspectives 2016, 4 (4)
    100. Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. Kyne, Kevin K.-C. Liu, Sarah J. Fink, Christopher J. O’Donnell. Synthetic approaches to the 2014 new drugs. Bioorganic & Medicinal Chemistry 2016, 24 (9) , 1937-1980.
    Load more citations

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect